Odronextamab
drugOn this page
Also known as REGN-1979Regn1979
Summary
Odronextamab (CHEMBL4298084) is a phase-3 clinical-stage antibody (ATC L01FX34) targeting MS4A1; indicated across 8 conditions including neoplasm of mature b-cells and diffuse large b-cell lymphoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- ATC class: L01FX34
- Targets: 1 (MS4A1)
- Indications: 8 conditions
- Clinical trials: 15
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298084 |
| Name | Odronextamab |
| Type | Antibody |
| Max phase | 3 |
| ATC | L01FX34 |
Also known as: Odronextamab, REGN-1979, Regn1979, REGN1979, ODRONEXTAMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| MS4A1 | CD20 (membrane-spanning 4-domains, subfamily A, member 1) | Binding | 0% | P11836 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): MS4A1.
Dominant GO biological processes
| GO term | Targets |
|---|---|
| store-operated calcium entry | 1 |
| humoral immune response | 1 |
| cell surface receptor signaling pathway | 1 |
| response to bacterium | 1 |
| B cell differentiation | 1 |
| B cell proliferation | 1 |
| B cell activation | 1 |
| B cell receptor signaling pathway | 1 |
| protein tetramerization | 1 |
| calcium ion import into cytosol | 1 |
| positive regulation of calcium ion import across plasma membrane | 1 |
Indications & clinical
Indications
8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm of mature B-cells | 3 | MONDO:0004949 | EFO:0000096 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| follicular lymphoma | 3 | MONDO:0018906 | MONDO:0018906 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| B-cell chronic lymphocytic leukemia | 1 | MONDO:0004948 | EFO:0000095 |
| B-cell non-Hodgkin lymphoma | 1 | MONDO:0015759 | EFO:1001938 |
| B-cell acute lymphoblastic leukemia | 1 | MONDO:0004947 | EFO:0000094 |
Clinical trials
Total trials: 15.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 5 |
| PHASE2 | 4 |
| PHASE1 | 4 |
| PHASE2/PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05991388 | PHASE2/PHASE3 | RECRUITING | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma |
| NCT06091254 | PHASE3 | RECRUITING | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma |
| NCT06091865 | PHASE3 | RECRUITING | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma |
| NCT06097364 | PHASE3 | ACTIVE_NOT_RECRUITING | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma |
| NCT06149286 | PHASE3 | RECRUITING | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma |
| NCT06230224 | PHASE3 | ACTIVE_NOT_RECRUITING | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma |
| NCT03888105 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies |
| NCT06784726 | PHASE2 | RECRUITING | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T |
| NCT06854159 | PHASE2 | RECRUITING | Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy |
| NCT07128641 | PHASE2 | RECRUITING | Odronextamab in Low Tumor Volume Advanced FL |
| NCT02651662 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies |
| NCT05685173 | PHASE1 | RECRUITING | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas |
| NCT06735664 | PHASE1 | RECRUITING | Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter’s Transformation |
| NCT06975787 | PHASE1 | RECRUITING | Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis |
| NCT05619367 | Not specified | AVAILABLE | A Compassionate Use (CU) Program of Odronextamab |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: MS4A1
- Diseases: neoplasm of mature B-cells, diffuse large B-cell lymphoma, follicular lymphoma